Dr. Jeffrey Borenstein, BBRF’s CEO and President, talks with Dr. Daniel Pine of the NIMH.

Dr. Sarah Lisanby has been deeply involved in developing and improving the safety of life-saving neuromodulatory treatments including electroconvulsive therapy (ECT) and magnetic seizure therapy (MST) for severe psychiatric illness.

We are pleased to present you with the 2023 Leading Research Achievements by BBRF Grantees, Prize Winners & Scientific Council Members.

Dr. Jeffrey Borenstein interviews Dr. Joan Luby of Washington University, St. Louis, whose research has changed views on the subject.

We are pleased to present you with the 2022 Leading Research Achievements by BBRF Grantees, Prizewinners & Scientific Council Members.

Dr. Mark S. George, a pioneer in the field, explains how TMS and related non-invasive brain stimulation technologies are changing the face of psychiatry.

Dr. George, a pioneer in the field, answers practical questions about TMS and other brain stimulation therapies for psychiatric illness.

We write about a novel idea to address brain-based disorders that has moved from theory to bedside in only 3 years. Called closed-loop neuromodulation, it involves using electrical stimulation—delivered via an implanted deep-brain stimulation (DBS) device—at a precise location in the brain. The

We offer A RESEARCHER’S PERSPECTIVE, based on a presentation given by Lisa M. Monteggia, Ph.D., of Vanderbilt University, at a zoom event hosted by BBRF. The topic of her presentation was “Studying Ketamine’s Rapid Effects to Unlock Secrets for Developing Better Antidepressants

Our PATHWAYS TO THE FUTURE story is about an unconventional approach to developing new psychiatric drugs. Based on an initiative by the National Institute of Mental Health, it’s called “Fast-Fail” and is designed to weed out the weakest drug candidates early in the process, to